Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | ACP3 | P15309 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8685464 | 0.87 | IDO1 (0.58) | IDO1MAOBLMNANR4A2PRKCA | |
| SCHEMBL9016833 | 0.84 | TAAR1 (0.53) | IDO1MAOBHTR2AHTR2CHTR2B | |
| SCHEMBL5317490 | 0.82 | KMT2A (0.55) | IDO1MAOBLMNASMN1; SMN2MAPT | |
| SCHEMBL1579060 | 0.82 | TAAR1 (0.50) | IDO1HTTHTR2AHTR2CHTR2B | |
| SCHEMBL5317470 | 0.81 | IDO1 (0.47) | IDO1MAOBNR4A2AR | |
| SCHEMBL30810184 | 0.81 | IDO1 (0.58) | IDO1MAOBNR4A2PRKCAPRKCD | |
| SCHEMBL29265687 | 0.78 | IDO1 (0.47) | IDO1MAOBLMNASMN1; SMN2TACR1 | |
| SCHEMBL27708411 | 0.78 | IDO1 (0.72) | IDO1MAOBNR4A2PRKCAPRKCD | |
| SCHEMBL2076848 | 0.77 | TSHR (0.50) | MAOBLMNASMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL30810275 | 0.76 | IDO1 (0.60) | IDO1MAOBNR4A2PRKCAPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10478423-B2 | Substituted indazole derivatives active as kinase inhibitiors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-11-19 | — | — | US | disclosed |
| US-20180289672-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2018-10-11 | — | — | US | disclosed |
| US-10028934-B2 | Substituted indazole derivatives active as kinase inhibitiors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2018-07-24 | — | — | US | disclosed |
| US-9597317-B2 | Substituted indazole derivatives active as kinase inhibitiors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-03-21 | — | — | US | disclosed |
| EP-2707359-B1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2016-11-30 | — | — | EP | disclosed |
| US-20160311776-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-10-27 | — | — | US | disclosed |
| US-20160310465-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-10-27 | — | — | US | disclosed |
| US-9408850-B2 | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-08-09 | — | — | US | disclosed |
| CN-103534239-B | There is the indazole derivatives of the replacement of kinase inhibitory activity | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-04-20 | — | — | CN | disclosed |
| US-20140080807-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-03-20 | — | — | US | disclosed |
| EP-2707359-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2014-03-19 | — | — | EP | disclosed |
| CN-103534239-A | Substituted indazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL | 2014-01-22 | — | — | CN | disclosed |
| WO-2012152763-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-11-15 | — | — | WO | disclosed |
| WO-2007069986-A1 | NEW OXABISPIDINE COMPOUNDS FOR THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080807-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K19 | IDO1 1043/4885MAOB 2843/4885LMNA 2673/4885 |
| US-20160310465-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | MAP3K20, MAP3K1, MAP3K5 | IDO1 871/4885MAOB 2559/4885LMNA 2676/4885 |
| US-10028934-B2 | Substituted indazole derivatives active as kinase inhibitiors | MAP3K20, MAP3K1, MAP3K5 | IDO1 871/4885MAOB 2559/4885LMNA 2676/4885 |
| US-20160311776-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | MAP3K20, MAP3K1, MAP3K5 | IDO1 871/4885MAOB 2559/4885LMNA 2676/4885 |
| US-10478423-B2 | Substituted indazole derivatives active as kinase inhibitiors | MAP3K20, MAP3K1, MAP3K5 | IDO1 871/4885MAOB 2559/4885LMNA 2676/4885 |
| US-20180289672-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITIORS | MAP3K20, MAP3K1, MAP3K5 | IDO1 871/4885MAOB 2559/4885LMNA 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.